Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
Report Highlights
The global market for nucleic acid aptamers reached $340.5 million in 2014. This market should grow to about $610.3 million in 2015 and about $5.4 billion in 2019, with a compound annual growth rate (CAGR) of 73.5% from 2014 to 2019.
Report Includes
- An overview of the specific applications for nucleic acid aptamers for therapeutic and diagnostic purposes, with a focus on applications judged to be commercially viable rather than enabling of basic research
- Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2019
- Identification of emerging technology growth opportunities in aptamer use as adjuvants for siRNA delivery, vaccines, and antisense technologies
- Examination of high growth and market potential segments of the industry, and new and established companies in the arena
- Comprehensive company profiles of major players in the industry.
Report Scope
This research report presents an in-depth analysis of the global nucleic acid aptamer market by technologies, applications and geographic regional markets. It includes key technologies involved, analyzes the capabilities and characteristics of aptamers in comparison with antibodies and lists specific areas where aptamers could find application. The evolving trends and technological developments in the field of aptamers have been studied in detail.
Special emphasis will be given to collaborative efforts, research innovations and investment clinical trials conducted. Patents will be discussed as well. This study also analyzes the aptamer-based drugs that have been developed or are in the pipeline for the treatment of various diseases. Impact analysis of the key drivers and factors affecting or influencing the growth of this market is also included.
The market for aptamer technologies is further categorized into enabling technology, diagnostic sensors and therapeutics. Enabling technology consists of SELEX technology, modified oligonucleotides, next-generation sequencing, nanoparticles and quantum dot labels, surface plasmon resonance and biolayer interferometry and bioinformatics. In terms of application the market is classified into diagnostics, therapeutics, research, biosensors, biomarker discovery and others.
Furthermore, diagnostics-based aptamers are used in environmental monitoring and food and water safety. They are also used for developing aptasensors for sensing small molecules and pathogens. Aptamers also find application in human clinical diagnostic assays for diagnosing diseases such as cancer, infectious diseases and other immunological diseases.
Aptamers are used in therapeutics and research as drug delivery vehicles in cancer, as a modifier of surgical implants and in bioseparation processes. Research areas include flow cytometry, mass spectrometry and Western blotting; they are also used as reagents and assays and as biosensors and biomarker molecules.
The market is segmented by regions into North America, Europe, Asia-Pacific and ROW. Companies profiled in this report include Ophthotech Corp., Alimera Sciences, AM Biotechnologies LLC, Alnylam Pharmaceuticals, Noxxon, Rina Gmbh, Regado Biosciences, Base Pair Biotechnologies Inc., Aptamer Sciences Inc., Aptasol (Aptamer Solutions) Ltd, Isis Pharmaceuticals, Neoventures Biotechnology Inc., Mitsui & Co. (U.S.A.) Inc., Quest Diagnostics, SomaLogic Inc. and Sumitomo Bakelite Co. Ltd.
Frequently Asked Questions (FAQs)
Analyst Credentials
Yojana Jeevane has more than four years of experience in market intelligence and business research. She has experience in the healthcare domain with respect to medical devices, the life sciences market, and in the chemical domain. She has frequently delivered research services that contain strategic recommendations and top business strategies to help market players make strategic decision. She holds an MBA in Marketing.
Report Highlights
The global aptamer market was valued at $40 million in 2011 and should reach nearly $99 million in 2012. Total market value is expected to reach nearly $3.7 billion in 2017 with a five-year compound annual growth rate (CAGR) of 106.3%.
Report Includes
- An overview of the specific applications for nucleic acid aptamers for therapeutic and diagnostic purposes, with a focus on applications judged to be commercially viable rather than enabling of basic research
- Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Identification of emerging technology growth opportunities in aptamer use as adjuvants for siRNA delivery, vaccines, and antisense technologies
- Examination of high growth and market potential segments of the industry, and new and established companies in the arena
- Comprehensive company profiles of major players in the industry.
Report Highlights
-
The global market for aptamers is poised for significant new market entrants in the near future. In 2009 this market was valued at $10 million. By 2014, this market is estimated to be worth $1.9 billion, a compound annual growth rate (CAGR) of nearly 68%.
-
Aptamer therapeutic markets were valued at $10 million in 2009 and should increase at a 55% compound annual growth rate (CAGR) to $1.2 billion in 2014.
-
Aptamer diagnostic markets were worth $26 million in 2010 and are expected to increase in value to $659 million in 2014, a compound annual growth rate (CAGR) of 124%.